STIM - NASDAQ

Neuronetics, Inc.

STIM·NASDAQ

$1.39

+2.3%

HealthcareMedical - Diagnostics & Research

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$96.73M

EPS-0.5900

P/E Ratio-2.36

Earnings Date08/04/2026

141.55M

Assets

3Y+21.0%

5Y+80.0%

10Y+471.0%

115.31M

Total Liabilities

3Y+93.0%

5Y+117.0%

10Y-43.0%

26.24M

Total Equity

-17%

3Y-54.0%

5Y+3.0%

10Y-115.0%

Neuronetics, Inc. Funding & Solvency Profile

STIM · NASDAQ

Current Assets

Cash & Cash Equivalents34.13M

Net Receivables16.89M

Inventory4.33M

Other Current Assets5.97M

Total Current Assets62 M

Non-Current Assets

Property, Plant & Equipment28.03M

Goodwill & Intangible Assets41.77M

Long-Term Investments249.00K

Other Non-Current Assets9.95M

Total Non-Current Assets38 M

Total Assets

141.55M

Financial Health Analysis

Current Ratio

2.02x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

4.39x

High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.

Working Capital

31 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

43% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

Financial Health Insight

Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.

Neuronetics, Inc. Balance Sheet

STIM • NASDAQ

Neuronetics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	34.1M	19.5M	59.7M	70.3M	94.1M	49M	75.7M	104.6M	29.1M	17M
Short-Term Investments	225K	206K	905K	1.5M	2.2M	1.9M	880K	0.0	0.0	0.0
Cash & Short-Term Investments	34.4M	19.7M	60.6M	71.9M	96.3M	50.8M	76.6M	104.6M	29.1M	17M
Net Receivables	16.9M	24.3M	17.8M	13.8M	7.8M	7.2M	6.6M	5.6M	4.3M	3.6M
Accounts Receivables	16.9M	24.3M	17.8M	13.8M	7.8M	7.2M	6.6M	5.6M	4.3M	3.6M
Inventory	4.3M	4.2M	8.1M	8.9M	6.6M	3.7M	2.8M	2.4M	2.5M	1.7M
Prepaids	0.0	3.1M	2.5M	2M	1.6M	1.1M	1.8M	0.0	1.1M	607K
Other Current Assets	6M	6.8M	4.8M	2.2M	3.1M	2.2M	689K	1.8M	0.0	0.0
Total Current Assets	61.6M	58.1M	93.8M	98.8M	115.3M	65M	88.5M	114.5M	37M	22.9M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	28M	33.3M	4.8M	5.3M	5.1M	4.1M	4.9M	1.4M	1.4M	1.6M
Goodwill	23.6M	18.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Intangible Assets	18.1M	19.6M	0.0	0.0	0.0	0.0	1.2M	1M	400K	0.0
Goodwill & Intangible Assets	41.8M	38.2M	0.0	0.0	0.0	0.0	1.2M	1M	400K	0.0
Long-Term Investments	249K	86K	661K	1.2M	1.7M	2.3M	1.7M	0.0	0.0	0.0
Tax Assets	0.0	0.0	0.0	0.0	0.0	0.0	-1.2M	0.0	0.0	0.0
Other Non-Current Assets	10M	11.1M	16.6M	11.6M	19.1M	7.2M	5.1M	171K	174K	250K
Total Non-Current Assets	80M	82.8M	22M	18.1M	25.9M	13.6M	11.7M	2.5M	1.9M	1.9M
Total Assets	141.6M	140.9M	115.8M	116.9M	141.2M	78.7M	100.2M	117M	38.9M	24.8M
LIABILITIES
CURRENT LIABILITIES
Total Payables	10.7M	12.3M	5.6M	3.1M	5M	4.5M	4.6M	3.8M	2.8M	1.8M
Accounts Payable	10.7M	11.1M	4.8M	2.4M	4.3M	3.7M	4.6M	3.8M	2.5M	1.5M
Other Payables	0.0	1.2M	818K	659K	664K	726K	0.0	0.0	322K	308K
Accrued Expenses	0.0	4.2M	3.8M	3M	2.5M	1.6M	2.6M	4.9M	4.5M	3.4M
Short Term Debt	5.6M	0.0	0.0	13.1M	0.0	0.0	11.8M	0.0	0.0	4.5M
Capital Lease Obligations (Current)	0.0	4.8M	845K	824K	670K	594K	559K	0.0	0.0	0.0
Tax Payables	0.0	619K	818K	659K	664K	726K	700K	606K	322K	308K
Deferred Revenue	753K	974K	1.6M	2M	2.5M	2M	2.2M	2.3M	2M	1.3M
Other Current Liabilities	13.5M	9M	8M	11.2M	5.1M	5M	5.9M	2.6M	2.7M	2.4M
Total Current Liabilities	30.5M	31.3M	19.8M	33.2M	15.7M	13.7M	27.7M	13.6M	12M	13.3M
NON-CURRENT LIABILITIES
Long Term Debt	65.8M	55.2M	59.3M	22.8M	35.3M	34.6M	19.9M	30.4M	29.6M	15.6M
Deferred Revenue (Non-Current)	48K	2K	200K	829K	1.5M	1.7M	2.1M	1.9M	2.3M	167K
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	19.9M	0.0	0.0	-167K
Other Non-Current Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	86K	187.8M	172.9M
Total Non-Current Liabilities	84.8M	77.8M	61.8M	26.6M	40.3M	39.5M	24.6M	32.4M	219.6M	188.6M
Capital Lease Obligations	18.9M	27.5M	3.2M	3.8M	4.2M	3.7M	3.2M	0.0	0.0	0.0
Total Liabilities	115.3M	109.1M	81.6M	59.8M	56M	53.2M	52.3M	46M	231.6M	201.9M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	117M	187.1M	172.3M
Common Stock	690K	557K	291K	273K	264K	191K	186K	177K	2K	2K
Additional Paid-In Capital	480.5M	446.9M	410M	402.7M	393.6M	302.8M	297.8M	291.9M	4.3M	3.7M
Retained Earnings	-458.8M	-419.8M	-376.1M	-345.9M	-308.7M	-277.5M	-250.1M	-221M	-196.9M	-180.9M
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2M	-1.8M	-1.7M
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8M	174M
Total Stockholders' Equity	22.4M	27.7M	34.2M	57.1M	85.2M	25.5M	47.9M	71M	-192.7M	-177.1M
Total Equity	26.2M	31.8M	34.2M	57.1M	85.2M	25.5M	47.9M	71M	-192.7M	-177.1M
Minority Interest	3.9M	4.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SUMMARY
Total Liabilities & Equity	141.6M	140.9M	115.8M	116.9M	141.2M	78.7M	100.2M	117M	38.9M	24.8M
Total Investments	474K	292K	1.6M	2.8M	3.9M	4.2M	2.6M	0.0	0.0	0.0
Total Debt	90.3M	82.6M	62.5M	39.7M	39.5M	38.3M	34.3M	30.4M	29.6M	20.1M
Net Debt	56.2M	63.2M	2.8M	-30.6M	-54.6M	-10.6M	-41.4M	-74.2M	409K	3.1M
Shares Outstanding	66,124,820	66,124,820	66,124,820	66,124,820	66,124,820	66,124,820	66,124,820	66,124,820	66,124,820	66,124,820

SEC Filings

STIM - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 29, 2026	May 28, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 22, 2026	May 18, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 05, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 05, 2026	May 05, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 09, 2026	May 28, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 06, 2026	March 31, 2026	2026	View Filing
S-3 S-3 N/A	March 17, 2026	March 17, 2026		View Filing
8-K 8-K 2026 N/A	March 17, 2026	March 17, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 17, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 02, 2026	March 02, 2026	2026	View Filing

Showing 1 to 10 of 181 filings

Related Guides

Blog Categories

Continue your STIM research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.